<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lederman, Lynne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Büller, Harry R.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">FXI-ASO May Represent a New Class of Antithrombotic Agents</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-10</style></pages><abstract><style  face="normal" font="default" size="100%">A single-stranded 2′-O-(2-methoxyethyl) antisense oligonucleotide to factor XI, is a promising new investigational antithrombotic agent that reduces the incidence of venous thrombosis in patients undergoing total knee replacement without increasing the incidence of bleeding episodes. The lower dose of FXI-ASO is noninferior to enoxaparin and the higher dose significantly reduces the risk of venous thromboembolism compared with enoxaparin.</style></abstract><number><style face="normal" font="default" size="100%">55</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>